Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting

ATLANTA, Aug. 09, 2017 -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that there will be four presentations and two posters on ILUVIEN^® at the 2017 American Society of Retinal Specialists (ASRS) Annual Meeting to be held August 11 through 15 in Boston.

"We look forward to the pivotal trial and real world evidence data on ILUVIEN being presented this year at ASRS, as it highlights the benefits of continuous microdosing,” said Dan Myers, CEO of Alimera. "These presentations highlight the ability for patients to reach driving vision and present visual outcomes achieved over time. Additionally, there will be data presented on the predictability and manageability of potential side effects from two large studies, one retrospective and one prospective."

Presentations:

Sunday, August 13, 2017, 1:13pm

• Inhibition of Diabetic Retinopathy Progression by 0.2 μg/day Fluocinolone Acetonide Implants: A Fellow-Eye Controlled Analysis. Raymond Iezzi, MD, MS Associate Professor of Ophthalmology, Mayo Clinic Department of Ophthalmology, Rochester, MN

Sunday, August 13, 2017, 1:27pm

• Long-Term Visual Acuity Response in Early Nonresponders Treated With 0.2 μg/day Fluocinolone Acetonide Implants in FAME Study. Daniel Roth, MD, Associate Clinical Professor, NJ Retina – Retina Vitreous Center, Department of Ophthalmology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Sunday, August 13, 2017, 4:03pm

• Predictability of IOP Response in Patients Receiving Prior Steroid and Subsequent 0.2 μg/day Fluocinolone Acetonide Intravitreal Implant Therapy. Seenu Hariprasad, MD, Shui-Chin Lee Professor of Ophthalmology, Chief, Vitreoretinal Service, Director of Clinical Research, University of Chicago Department of Ophthalmology

Sunday August 13, 2017, 4:08pm

• Initial Efficacy, Anatomic and Safety Outcomes After Fluocinolone Acetonide 0.2 μg/Day Implant in DME: The PALADIN Real-World Observational Study. Jay Prensky, MD, FACS, Pennsylvania Retina Specialists, PC, Camp Hill, PA

             
Posters:

• The CONSTANT analysis: area-under-the-curve evaluation comparing fluocinolone acetonide 0.2 μg/day with ranibizumab over a 36-month study period (Poster # 214). Jeffrey Gross, MD, Founder, Carolina Retina Center, 7620 Trenholm Rd., Columbia, SC
   
• Effect of Fluocinolone Acetonide 0.2μg/Day Implant on the Decision to Drive in Patients with Diabetic Macular Edema: Report from FAME Trial, (Poster on Demand). Dilraj Grewal, MD, Associate Professor of Ophthalmology, Duke Eye Center, Duke University School of Medicine, 2351 Erwin Road, Durham, NC

About ILUVIEN

www.ILUVIEN.com.

ILUVIEN'S U.S. Indication

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. As the population of people with diabetes increases, Alimera expects the annual incidence of diagnosed DME to increase, as well.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

For press inquiries:
Katie Brazel
for Alimera Sciences 
404-317-8361
[email protected]

For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
[email protected]